Shares of Kadmon Holdings Inc (NYSE:KDMN) have received a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $13.25.

KDMN has been the subject of a number of recent analyst reports. Zacks Investment Research cut Kadmon from a “hold” rating to a “sell” rating in a report on Tuesday, May 15th. ValuEngine raised Kadmon from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Jefferies Group raised their price target on Kadmon to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kadmon in a report on Friday, March 9th. Finally, Piper Jaffray Companies reaffirmed a “positive” rating and set a $9.00 price target (up from $7.00) on shares of Kadmon in a report on Tuesday, February 13th.

KDMN stock traded down $0.10 during midday trading on Thursday, reaching $3.62. 166,888 shares of the company’s stock traded hands, compared to its average volume of 707,919. Kadmon has a 1-year low of $2.05 and a 1-year high of $5.86. The stock has a market capitalization of $292.33 million, a price-to-earnings ratio of -2.55 and a beta of 3.75.

Kadmon (NYSE:KDMN) last released its quarterly earnings results on Tuesday, May 8th. The company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.03. The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $2.67 million. equities research analysts forecast that Kadmon will post -1.12 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Acuta Capital Partners LLC boosted its position in Kadmon by 21.1% in the 1st quarter. Acuta Capital Partners LLC now owns 5,950,000 shares of the company’s stock valued at $25,288,000 after buying an additional 1,035,000 shares during the last quarter. Millennium Management LLC boosted its position in Kadmon by 490.1% in the 1st quarter. Millennium Management LLC now owns 1,847,444 shares of the company’s stock valued at $7,852,000 after buying an additional 1,534,371 shares during the last quarter. Goldentree Asset Management LP boosted its position in Kadmon by 673.6% in the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock valued at $5,834,000 after buying an additional 1,403,397 shares during the last quarter. BlackRock Inc. boosted its position in Kadmon by 639.8% in the 1st quarter. BlackRock Inc. now owns 1,540,225 shares of the company’s stock valued at $6,546,000 after buying an additional 1,332,035 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its position in Kadmon by 35.5% in the 1st quarter. Sphera Funds Management LTD. now owns 1,490,000 shares of the company’s stock valued at $6,333,000 after buying an additional 390,000 shares during the last quarter. Hedge funds and other institutional investors own 64.07% of the company’s stock.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.